Sensorion Hosting Key Opinion Leader Webinar with Dr. Thomas Lenarz on the GJB2 Gene Related Hearing Loss on May 10, 2021 Regulatory News: Sensorion (FR0012596468 ALSEN) a pioneering clinical-stage biotechnology company which specializes in the development of novel therapies to restore, treat and prevent within the field of hearing loss disorders, announced today that it will host a key opinion leader (KOL) webinar on GJB2-Related Genetic Hearing Loss on Monday, May 10, 2021 at 10am Eastern Time. The event will feature a presentation by KOL Thomas Lenarz, M.D. Ph.D., Medical University of Hannover, who will discuss the clinical aspects, current treatments landscape and unmet medical needs in treating patients with a pediatric onset of GJB2-related hearing loss as well as the role of the GJB2 gene. Dr. Lenarz will be available to answer questions following the formal presentations.